Targeting Th17 cytokines such as IL-6, IL-17, and IL-23 is an effective strategy in rheumatoid arthritis, psoriasis, psoriatic arthritis, and inflammatory bowel disease (IBD) (23–26). This evidence concerns the gene IL17A and psoriasis.